Drugs approved by the FDA for treatment of acute leukemia and related diseases
| Drug . | Indication . |
|---|---|
| Regular approval | |
| Asparaginase | Treatment of ALL |
| Cytarabine | Remission induction in AML in adults and children |
| Daunorubicin | Remission induction in AML in adults and ALL in adults and children |
| Idarubicin | Treatment of AML in adults |
| 6-Mercaptopurine | Remission induction and maintenance of ALL |
| Mitoxantrone | Initial therapy of AML |
| Teniposide | Induction therapy in recurrent ALL in children |
| Thioguanine | Treatment of AML |
| Vincristine | Treatment of acute leukemia |
| Tretinoin | Remission induction in recurrent APL |
| Arsenic trioxide | Remission induction, consolidation in recurrent APL |
| Dasatinib | Philadelphia chromosome-positive ALL in adults resistant or intolerant to prior therapy |
| Azacitidine | Treatment of myelodysplasia |
| Decitabine | Treatment of myelodysplasia |
| Lenalidomide | Treatment of low/intermediate-1 risk MDS associated with 5q– |
| Accelerated approval | |
| Gemtuzumab ozogamicin | Treatment of CD33+ AML in first relapse in adults ≥ 60 y not candidates for chemotherapy |
| Clofarabine | Treatment of childhood ALL recurrent after ≥ 2 prior therapies |
| Nelarabine | T-cell ALL recurrent after ≥ 2 therapies in children and adults |
| Drug . | Indication . |
|---|---|
| Regular approval | |
| Asparaginase | Treatment of ALL |
| Cytarabine | Remission induction in AML in adults and children |
| Daunorubicin | Remission induction in AML in adults and ALL in adults and children |
| Idarubicin | Treatment of AML in adults |
| 6-Mercaptopurine | Remission induction and maintenance of ALL |
| Mitoxantrone | Initial therapy of AML |
| Teniposide | Induction therapy in recurrent ALL in children |
| Thioguanine | Treatment of AML |
| Vincristine | Treatment of acute leukemia |
| Tretinoin | Remission induction in recurrent APL |
| Arsenic trioxide | Remission induction, consolidation in recurrent APL |
| Dasatinib | Philadelphia chromosome-positive ALL in adults resistant or intolerant to prior therapy |
| Azacitidine | Treatment of myelodysplasia |
| Decitabine | Treatment of myelodysplasia |
| Lenalidomide | Treatment of low/intermediate-1 risk MDS associated with 5q– |
| Accelerated approval | |
| Gemtuzumab ozogamicin | Treatment of CD33+ AML in first relapse in adults ≥ 60 y not candidates for chemotherapy |
| Clofarabine | Treatment of childhood ALL recurrent after ≥ 2 prior therapies |
| Nelarabine | T-cell ALL recurrent after ≥ 2 therapies in children and adults |